Before founding NextCODE with Hannes Smarason, Dr. Gulcher co-founded deCODE genetics. Dr. Gulcher became Vice President for Research and Development and finally served as the company’s Chief Scientific Officer starting in 2003. deCODE took public and sold to Amgen for $415 million in 2012.
The deCODE launch coincided with a position on staff in the department of neurology at Beth Israel Hospital in Boston, Mass. and Harvard Medical School, where he served from 1993 to 1998.
Dr. Gulcher received his PhD and MD from the University of Chicago in 1986 and 1990, respectively, and completed his neurology residency at the Longwood Program of the neurology departments of Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center of Harvard Medical School in 1996. He received a bachelor’s degree in chemistry/physics from Michigan State University in 1981. He has authored 186 peer-reviewed publications on the genetics of common/complex diseases.